Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tocilizumab and Infliximab on COVID-19
IRCT20220208053970N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of tocilizumab and infliximab in coronavirus disease 2019 (COVID-19), sponsored by Shahrekord University of Medical Sciences. Started Mar 2022; status: completed.
02
Drugs
tocilizumabinfliximab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20220208053970N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220208053970N1.